



HHS Public Access

Author manuscript

Bioorg Med Chem. Author manuscript; available in PMC 2021 March 29.

Published in final edited form as:

Bioorg Med Chem. 2021 January 01; 29: 115877. doi:10.1016/j.bmc.2020.115877.

Design and development of FGF-23 antagonists: Definition of the pharmacophore and initial structure-activity relationships probed by synthetic analogues

Ryan P. Downs^{a,1}, Zhousheng Xiao^{b,1}, Munachi O. Ikedionwu^{a,1}, Jacob W. Cleveland^a, Ai Lin Chin^a, Abigail E. Cafferty^a, L. Darryl Quarles^b, Jesse D. Carrick^{a,*}

^aDepartment of Chemistry, Tennessee Technological University, Cookeville, TN 38505-0001, USA

^bDepartment of Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38165, USA

Abstract

Hereditary hypophosphatemic disorders, TIO, and CKD conditions are believed to be influenced by an excess of Fibroblast Growth Factor-23 (FGF-23) which activates a binary renal FGFRs / α -Klotho complex to regulate homeostatic metabolism of phosphate and vitamin D. Adaptive FGF-23 responses from CKD patients with excess FGF-23 frequently lead to increased mortality from cardiovascular disease. A reversibly binding small molecule therapeutic has yet to emerge from research and development in this area. Current outcomes described in this work highlight efforts related to lead identification and modification using organic synthesis of strategic analogues to probe structure-activity relationships and preliminarily define the pharmacophore of a computationally derived hit obtained from virtual high-throughput screening. Synthetic strategies for the initial hit and analogue preparation, as well as preliminary cellular *in vitro* assay results highlighting sub micromolar inhibition of the FGF-23 signaling sequence at a concentration well below cytotoxicity are reported herein.

Keywords

FGF-23; Antagonist; Arene; Oxime; Cross-coupling

*Corresponding author: jcarrick@tntech.edu (J.D. Carrick).

¹These authors contributed equally to the published work.

Author contributions

The manuscript was composed from experimental, theoretical, and written contributions of all authors. All authors have given approval to the final version of the manuscript.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary material

Synthetic procedures for the construction of select aldehydes requisite to analogue formation, in addition to ¹H and ¹³C NMR data for all analogues not previously disseminated in the primary literature. Automated flash column chromatograms for select compounds not previously reported. This material is available free of charge. Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bmc.2020.115877>.

1. Introduction

FGF-23 is a bone-derived signaling biomolecule that activates a FGFR/ α -Klotho binary complex in the kidney to regulate renal metabolism of phosphate and vitamin-D.¹ Excess FGF-23 results in rare hereditary hypophosphatemic disorders, such as X-linked hypophosphatemia² (XLH), the autosomal recessive hypophosphatemic (ARH) bone-softening disorder rickets,³ and acquired tumor-induced osteomalacia (TIO).⁴ Adaptive increases in FGF-23 also maintain phosphate and vitamin D homeostasis in chronic kidney disease (CKD) and is associated with increased cardiovascular (CV) mortality.⁵ Recently, antagonizing FGF-23 with a blocking antibody has been successful in treating hypophosphatemic disorders caused by excess FGF-23. In this regard, a FGF-23 monoclonal antibody KRN23 (Crysvita®, burosumab) has been approved for treatment of XLH.⁶ There is an unmet clinical therapeutic need for an efficacious small molecule antagonist of FGF-23 that is selective, reversible, and non-biologic in nature as over suppression of FGF-23 has potential toxicities, including hyperphosphatemia and vascular calcifications. Because of the disadvantages associated with parenteral administration of biologics, developing an orally available small molecule drug to block the FGF-23 signaling sequence would have several potential advantages, including ease of administration, shorter half-life, effective dose-titration to more precisely inhibit FGF-23, and possibly result in greater efficacy and safety.

Virtual high-throughput screening (vHTs) via supercomputing utilizing structure-based molecular dynamics simulations⁷ employing ensemble docking strategies⁸ afforded ZINC13407541 (parent molecule, named as **1**) as an *in silico* hit for selective FGF-23 antagonism (Fig. 1). Cellular assays validated **1** as a selective inhibitor of the FGF-23 signaling sequence in an *in vitro* heterologous cell expression model, as well as isolated renal tubules *ex vivo*.⁹ Preliminary animal model studies with a murine species that overexpressed FGF-23 resulted in dose-dependent inhibition, as well as partial reversal of hypophosphatemic effects. With *in vitro* and preliminary animal model efficacy of **1** confirmed, medicinal chemistry efforts transitioned to synthetic route optimization and elaboration towards formulating a lead compound from the original hit while further refining the original scaffold for greater efficacy and ease of synthetic preparation. Dissemination of the synthetic route to the prepared antagonist analogues, definition of the pharmacophore, probing of structure–activity relationships via synthetic analogues, and the optimization of *in vitro* potency of prepared molecules are reported.

2. Results

2.1. Synthesis

The synthetic construction of analogues as novel FGF-23 antagonists discovered from vHTS affording **1** was anchored from a common scaffold derived in several synthetic steps from readily available cycloalkanone starting materials (Scheme 1). Retrosynthetic analysis of **1** using standard functional group interconversions of oxime formation¹⁰ and metal-mediated transformations through the Suzuki-Miyaura cross-coupling¹¹ via known chemistry was envisioned.¹² The convergency of the route allowed maximum flexibility of functionality towards pharmacophore mapping and optimization towards lead identification. Analogues were proposed to initially focus on variation of functionality to maintain conjugation of the

extended π -system through the carbonyl and cycloalkene. Evaluation of ring size through the 5- and 6-membered common rings, in addition to heteroarene constructs was also performed (Scheme 2).

arene and heteroarene constructs were evaluated. Extension of this strategy towards aryl and Conversion of cyclopentanone to 2-bromocyclopentene carbaldehyde using a modified Vilsmeier¹³ protocol adapted from Lipton¹⁴ afforded the desired synthon for metal-mediated coupling (**4**) in 70% yield. This reaction was amenable towards the formation of the 5-membered bromo-cyclopentene carbaldehyde **4** or the 6-membered homologue **5**.¹⁵ Moving forward, treatment of **4** or **5** with potassium styrenyltrifluoroborate¹⁶ using Pd-catalysis via Suzuki-Miyaura cross-coupling¹⁷ conditions optimized in our laboratory¹⁸ resulted in the production of the necessary advanced aldehyde intermediates **6** and **7** for subsequent functional group interconversion.¹⁹ Conversion to the oxime **1** was successful under standard conditions resulting in a 46% yield over three steps from cyclopentanone (**2**) on micro scale. During route scouting and validation it was observed that **4** could be directly converted into the oxime **10** in high purity.²⁰ Intermediate **10** was evaluated in parallel Suzuki-Miyaura cross-coupling reactions towards the production of the functionalized oxime with potassium styrenyltrifluoroborate, but did not afford the desired product in comparable yield, or purity. The chemistry described in Scheme 1 was the basis for the production of all requisite functionalized aldehydes, including the pyridine, benzene, and thiophene oxime analogues of **1** (Scheme 2)²¹

With an established protocol to install the requisite carbon functionality onto the desired scaffolds, focus turned towards the completion of the oxime derivatives described in Table 1 for the definition of the pharmacophore and evaluation of structure-activity relationships probed by synthetic analogues. The original vHTS hit was divided into three zones for functional group manipulation towards understanding the impacts of various structural features of a given antagonist analogue on *in vitro* efficacy (Fig. 1). Zone 1 analogues evaluated the significance of the hydrogen bond donor oxime and related methyl oxime derivative. Zone 2 analogues studied the impact of saturated ring size through the common 5- and 6-membered cycloalkanes, in addition to substitution of phenyl, pyridinyl, and thiophene cores. Whereas, Zone 3 analogues of **1** probed the necessity of extended π -conjugation through the styrenyl, or direct connect aryl derivatives. The initial optimization analogue scope of **1** encompassed diverse functionality including conjugated styrenyl derivatives with aldehydes **4**, **5**, **11**, **12**, and **15**. Aliphatic analogues (**8f**, **8g**, and **8t**) were critical for evaluating the importance of conjugation to maintenance of more potent biological activity. A vinyl derivative lacking any aryl ring (**8u**), as well as direct connect aryl moieties (**8l-8s**) were prepared. Aryl moieties with broad substitution patterns (*o*, *m*, *p*, or poly-) were explored while concomitantly ascertaining the significance of resonance- and electron-donating, in addition to electron-withdrawing functionality. Most oxime end products were afforded as one major stereoisomer in above 75% average isolated, purified yield. Structural confirmation of prepared analogues was facilitated via ¹H- and ¹³C NMR in concert with high-resolution mass spectrometry. The unoptimized current synthetic route is reproducibly robust and can support future assay studies without extensive reoptimization.²² With the realization of a viable synthetic strategy to produce relevant analogues of **1** for

structure-activity studies, the focus of the research shifted to evaluating the *in vitro* efficacy of the prepared analogues.

2.2. In vitro efficacy

To evaluate the potency of the newly synthesized compounds, *in vitro* efficacy of the prepared antagonists, as measured by percent inhibition using HEK-293 T cells expressing FGFRs/ α -Klotho and FGF-23-induced ERK reporter activation as the read out, were performed (Fig. 2). Five distinct groups at 10 μ M concentration were identified: Group I = 100% inhibition, Group II = 70–90% inhibition, Group III = 50–70% inhibition, Group IV = 20–50% inhibition, and Group V < 20% inhibition. Further structure / activity analysis revealed that the aldehyde precursor to **1**²³ (**6a**) demonstrated 6-fold lower biological activity (%Max inhibition 46%) than **1** which underscores the significance of the oxime moiety to the pharmacophore of **1** in Group IV. The potential for hydrogen bonding of the oxime versus the methyl oxime **8e** which, displayed <20% inhibition, signifies the importance of this functional group to the antagonist pharmacophore. Removal of aromatic functionality (**8h**, **8i**, or **8t**), or manipulation of the conjugation in **1** with analogues **8f** and **8g** proved deleterious to biological activity.

Assessment of substitution of weakly donating alkyl substituents on the aryl ring of **8a** of core **4**, as well as the resonance-donating methoxy-substituent of **8b** highlighted the significance of these structural amendments to overall potency. Interestingly, manipulation of the cores from **4** to **5**, **11**, or **12**, while retaining the 4-methylstyrenyl substituent (**9b**, **13a**, or **14b**) as part of the Zone 2 analogues, afforded the most potent analogues to **1**, while demonstrating the relevance of this substituted to biological activity. Electrocyclization analogue **8v**, afforded during chromatography of **1**, and postulated to potentially be an *in vivo* metabolite of **1**, produced poor activity results as a constituent of Group V did not validate the aforementioned hypothesis.²⁴ Subsequent effort targeted the preparation of analogues which were devoid of the transalkenyl double bond which bridged the core to the aryl substituents. Excision of the interstitial trans-double bond alleviates two rotatable bonds,²⁵ modulates lipophilicity slightly, and affords more rapid access to future functionally group diverse examples *vide infra*. Compounds **8m** and **8o**, direct-connect, aromatic derivatives of **8a** and **8b**, which negated the vinyl group, demonstrated lower than half biological activity compared to **1** and further validated the relevance of extension of conjugation, or electron density, as potential influences on increased activity. Thiophene analogues of **1** were extremely challenging to synthesize and purify. Substantive efforts afforded **16a** and **16b** which performed inferiorly to **1**. Probing the structural nature of the oxime with respect to biological activity as part of the Zone 3 analogues, including the methyl oxime **8a**, aldoxime **1** afforded slightly higher potency. Based on the initial *in vitro* results presented, eight analogues were selected from Groups I to IV for IC₅₀ determinations (Table 2).

The IC₅₀ values of prepared FGF-23 antagonist analogues evaluated ranged from 0.14 μ M (**13a**) to 31 μ M (**6a**) with a ranked order of **13a** (0.14 μ M), **8a** (0.20 μ M), **8c** (0.37 μ M), **14b** (0.39 μ M), **9b** (0.52 μ M), **8n** (2.79 μ M), **8l** (10 μ M), **8o** (12.3 μ M) and **6a** (31 μ M), respectively. **8n**, **8l**, and **8o** decreased maximum inhibition activity (%Max inhibition 60 ~

70%) in Group II, III, and IV. On the aryl ring of **8a** and **8c**, a 4-position electron-donating substituent CH₃ for **8a** and the resonance-donating substituent OCH₃ for **8c** largely increases the efficacy, leading to 10 ~ 25-fold higher potency for inhibiting FGF-23 activity when compared to **1** (IC₅₀ 5.0 μM) in Group I. The presence of the double bond in **8c** compared to **8o** resulted in an order of magnitude increase in activity for the former, as compared to the latter. In addition, incorporation of a 6-membered cyclohexenyl ring (**9b**), aromatic ring (**13a**) or heteroaromatic core (**14b**) on these analogues resulted in 10 ~ 36-fold higher potency for inhibiting FGF-23 activity as opposed to **1** (IC₅₀ 5.0 μM) in Group I. Cytotoxicity assays revealed that all the test compounds have no obvious cytotoxicity from 10⁻⁹ M to 10⁻⁵ M, which is further underscored by the fact that IC₅₀ values were dramatically lower than EC₅₀ values. Only **8n** showed markedly stimulated cellular LDH release at a concentration of 10⁻⁴ M with 2.30 × 10² μM EC₅₀. The EC₅₀ values of other compounds with a ranked order are **8a** (5.70 × 10² μM), **13a** (6.90 × 10² μM), **1** (1.41 × 10³ μM), **8o** (1.91 × 10³ μM), and **14b** (2.41 × 10³ μM), respectively. Future studies will examine the adsorption, distribution, metabolism, excretion, selectivity and toxicity of these lead compounds.

3. Conclusion

In conclusion, we have described an efficiently convergent and diversified approach to small-molecule antagonists of the bone-derived signaling biomolecule FGF-23 from an initial vHTS hit. Structure-activity relationships were probed from the preparation of expansive synthetic analogues which have preliminarily defined the requisite pharmacophore of this antagonist class requiring a polar oxime with a conjugated aryl group with electron-donating substituents being able to achieve sub 1 μM inhibition in the FGF-23 signaling sequence from *in vitro*, cellular IC₅₀ assays. Subsequent lead optimization efforts with respect to first pass metabolic stability, oral availability, toxicity, and animal model studies are ongoing in these laboratories and will be reported in due course.

4. Experimental section

General Considerations:

All reagents were purchased from U.S. chemical suppliers, stored according to published protocols, and used as received unless indicated otherwise. All experiments were performed in oven- or flame-dried glassware. Reaction progress was monitored using thin-layer chromatography on glass-backed silica gel plates and/or ¹H NMR analysis of crude reaction mixtures. R_F values for compounds that resulted in a concentrically observed spot on normal phase silica gel are reported using the conditions listed. All melting points are reported as observed and uncorrected. All reported yields listed are for pure compounds and corrected for residual solvent or stereoisomeric impurities, if applicable, from ¹H NMR spectroscopy unless otherwise indicated. All ¹H and ¹³C NMR data was acquired from a 500 MHz multinuclear spectrometer with broad-band N₂ cryoprobe. Chemical shifts are reported using the δ scale and are referenced to the residual solvent signal: CDCl₃ (δ 7.26) and CD₃OD (3.31) for ¹H NMR and chloroform (δ 77.16), CD₃OD (39.00), and (CD₃)₂CO (29.84) for ¹³C NMR. Splittings are reported as follows: (s) = singlet, (d) = doublet, (t) = triplet, (dd) =

doublet of doublets, (ddd) = doublet of doublet of doublets, (dt) = doublet of triplets, (br) = broad, (m) = multiplet, and pent = pentet. Infrared spectral data was acquired from the (form) listed. High resolution mass spectrometry (HRMS) data was obtained utilizing electron impact ionization (EI) with a magnetic sector (EBE trisector), double focusing-geometry mass analyzer. The compounds were stored in the $-20\text{ }^{\circ}\text{C}$ freezer and were tested via *in vitro* assay. Recombinant human FGF-23 was purchased from R&D Systems (Minneapolis, MN, USA).

General Procedure for Oxime Formation: To an 8 mL reaction vial equipped with a magnetic stir bar at ambient temperature was charged the required aldehyde, sodium acetate (1.50 equiv), and hydroxylamine hydrochloride (1.50 equiv) in ethanol:H₂O (3:1) (10 vol) at ambient temperature. The reaction was continued for 16 h upon which time an aliquot was removed and analyzed by ¹H NMR. Concentration of the crude reaction mixtures under reduced pressure at ambient temperature followed by purification on normal phase silica gel using automated flash-column chromatography with MTBE:hexanes, EtOAc:hexanes, or MeOH:DCM gradient mobile phases afforded the compounds described in the listed yields.

2-Styryl-cyclopent-1-enecarbaldehyde oxime (1):

Prepared according to the general procedure discussed above with **6a**²⁶ (0.54 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.58$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; isolated yield 0.195 g, 93%; orange solid; mp = 149.7–152.9 $^{\circ}\text{C}$; ¹H NMR (500 MHz, CDCl₃): δ 8.41 (s, 1H), 7.45 (d, $J = 7.5$ Hz, 2H), 7.36–7.32 (m, 2H), 7.28–7.24 (m, 1H), 7.23 (d, $J = 16.0$ Hz, 1H), 6.62 (d, $J = 16.0$ Hz, 1H), 2.78–2.69 (m, 4H), 1.98 (pent, $J = 7.5$ Hz, 2H); ¹³C NMR (125 MHz, CDCl₃): δ 146.4, 145.8, 137.2, 133.5, 132.2, 128.9, 128.2, 126.8, 121.2, 33.8, 32.9, 21.9; IR (ATR-CDCl₃): $\bar{\nu}_{max} = 3247$, 3032, 2953, 2850, 1649, 1599, 1510, 1006, 948, 939, 753, 693 cm^{-1} ; HRMS (EI): m/z calculated for C₁₄H₁₅NO: 213.1154; found: 213.1155.

2-(2-*p*-Tolyl-vinyl)-cyclopent-1-enecarbaldehyde oxime (8a):

Prepared according to the general procedure discussed above with **6b** (0.30 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.51$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; isolated yield 0.051 g, 75%; off-white solid; mp = 172.9–177.4 $^{\circ}\text{C}$; ¹H NMR (500 MHz, CDCl₃): δ 8.40 (s, 1H), 7.35 (d, $J = 7.5$ Hz, 2H), 7.19 (d, $J = 16.0$ Hz, 1H), 7.15 (d, $J = 7.5$ Hz, 2H), 6.60 (d, $J = 16.0$ Hz, 1H), 2.78–2.68 (m, 4H), 2.35 (s, 3H), 1.97 (pent, $J = 7.5$ Hz, 2H); ¹³C NMR (125 MHz, CDCl₃): δ 146.4, 145.6, 138.0, 134.4, 132.9, 132.0, 129.5, 126.6, 120.2, 33.7, 32.7, 21.7, 21.2; IR (ATR-CDCl₃): $\bar{\nu}_{max} = 3200$, 2955, 2847, 1615, 1583, 1511, 1465, 1006, 940, 801 cm^{-1} ; HRMS (EI): m/z calculated for C₁₅H₁₇NO: 227.1310; found: 227.1302.

2-[2-(4-Methoxy-phenyl)-vinyl]-cyclopent-1-enecarbaldehyde oxime (8b):

Prepared according to the general procedure discussed above with **6c** (0.44 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.30$, 20% EtOAc:hexanes; purified using

automated flash column chromatography using an MTBE:hexanes gradient mobile phase; isolated yield 0.074 g, 99%; off-white solid; mp = 151.2–153.0 °C; ^1H NMR (500 MHz, CDCl_3): δ 8.40 (s, 1H), 7.42–7.38 (m, 2H), 7.11 (d, J = 16.0 Hz, 1H), 6.91–6.86 (m, 2H), 6.58 (d, J = 16.0 Hz, 1H), 3.83 (s, 3H), 2.77–2.68 (m, 4H), 1.97 (pent, J = 7.5 Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 159.7, 146.5, 14538, 132.4, 131.7, 130.1, 128.1, 119.3, 114.4, 55.5, 33.8, 32.8, 21.8; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}}$ = 3260, 3032, 3002, 2841, 1602, 1510, 1248, 1174, 904, 819, 726 cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{15}\text{H}_{17}\text{NO}_2$: 243.1259; found: 243.1265.

2-[2-(4-Fluoro-phenyl)-vinyl]-cyclopent-1-enecarbaldehyde oxime (8c):

Prepared according to the general procedure discussed above with **6d** (0.30 mmol, 1.00 equiv) and hydroxylamine hydrochloride. The crude mixture was concentrated under reduced pressure and the resulting residue was partitioned between EtOAc:H₂O in a separatory funnel where the organic layer was separated. The aqueous layer was back extracted with 2 × 10 mL portions of ethyl acetate. The combined organic layers were washed with 10 mL of a saturated aqueous NaCl solution, dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure to afford the title compound: R_F = 0.49, 20% MTBE:hexanes; isolated yield 0.067 g, 99%; tan solid; decomposed upon heating for mp analysis; ^1H NMR (500 MHz, CDCl_3): δ 8.40 (s, 1), 7.45–7.40 (m, 2H), 7.14 (d, J = 15.7 Hz, 1H), 7.06–7.01 (m, 2H), 6.58 (d, J = 15.7 Hz, 1H), 2.77 (m, 4H), 1.98 (pent, J = 7.5 Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 163.9, 161.7, 146.1, 145.6, 133.5, 133.4 (J = 3.0 Hz), 128.3 (J = 8.5 Hz), 121.0 (J = 2.0 Hz), 115.9 (J = 21.8 Hz), 33.8, 32.9, 21.8; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}}$ = 3255, 2964, 600, 1507, 1224, 855, 819 cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{14}\text{H}_{14}\text{FNO}$: 231.1059; found: 231.1062.

2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-cyclopent-1-enecarbaldehyde oxime (8d):

Prepared according to the general procedure discussed above with **6e** (0.86 mmol, 1.00 equiv) and hydroxylamine hydrochloride. The crude mixture was concentrated under reduced pressure and the resulting residue was partitioned between EtOAc: H₂O in a separatory funnel where the organic layer was separated. The aqueous layer was back extracted with 2 × 10 mL portions of ethyl acetate. The combined organic layers were washed with 10 mL of a saturated aqueous NaCl solution, dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure to afford the title compound, R_F = 0.47, 20% MTBE:hexanes; isolated yield 0.132 g, 52%; gold solid; mp = 179.5–181.2 °C; ^1H NMR (500 MHz, CDCl_3): δ 8.41 (s, 1H), 7.60 (d, J = 8.4 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 16.0 Hz, 1H), 6.63 (d, J = 16.0 Hz, 1H), 2.80–2.72 (m, 4H), 2.0 (pent, J = 7.5 Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 145.9, 144.9, 140.7, 135.3, 130.4, 129.8 (d, J = 31.8 Hz), 126.83, 126.8X (overlaps with 126.83), 125.8 (d, J = 3.6 Hz), 123.5, 33.7, 30.0, 21.8; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}}$ = 3240, 2965, 2838, 1611, 1457, 1320, 1165, 1119, 1108, 1066, 867, 819 cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{15}\text{H}_{14}\text{F}_3\text{NO}$: 281.1027; found: 281.1037.

2-Styryl-cyclopent-1-enecarbaldehyde O-methyl-oxime (8e):

Prepared according to the general procedure discussed above with **6a** (0.16 mmol, 1.00 equiv) and methoxyamine hydrochloride, $R_F = 0.39$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; isolated yield 0.030 g, 89%; orange solid; mp = 139.0–141.5 °C; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.37 (s, 1H), 7.46–7.42 (m, 2H), 7.36–7.31 (m, 2H), 7.27–7.23 (m, 1H), 7.21 (d, $J = 16.0$ Hz, 1H), 6.60 (d, $J = 16.0$ Hz, 1H), 3.94 (s, 3H), 2.74 (t, $J = 7.5$ Hz, 4H), 1.97 (pent, $J = 7.5$ Hz, 2H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 145.1, 144.8, 137.4, 133.9, 131.8, 128.9, 128.1, 126.7, 121.4, 62.0, 33.8, 33.0, 21.9; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}} = 3031, 2935, 2846, 2816, 1601, 1588, 1495, 1448, 1055, 750, 691$ cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{15}\text{H}_{17}\text{NO}$: 227.1310; found: 227.1315.

2-Phenethyl-cyclopent-1-enecarbaldehyde oxime (8f):

Prepared according to the general procedure discussed above with **6f** (0.25 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.49$, 20% MTBE: hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; isolated yield 0.020 g, 37%; pale-brown oil; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 7.99 (s, 1), 6.60–6.53 (m, 2H), 6.51–6.43 (m, 3H), 2.02 (t, $J = 7.5$ Hz, 1H), 1.88–1.79 (m, 4H), 1.76 (t, $J = 7.5$ Hz, 2H), 1.15 (pent, $J = 7.5$ Hz, 2H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 149.9, 146.5, 141.5, 130.0, 128.5, 128.4, 126.2, 37.2, 34.7, 32.1, 30.9, 22.0; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}} = 3204, 3062, 2948, 2921, 1640, 1602, 1496, 1453, 968, 927, 745, 703$ cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{14}\text{H}_{17}\text{NO}$: 215.1310; found: 215.1305.

2-(3-Phenyl-propenyl)-cyclopent-1-enecarbaldehyde oxime (8g):

Prepared according to the general procedure discussed above with **6g** (0.40 mmol, 1.00 equiv) and hydroxylamine hydrochloride: $R_F = 0.55$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; isolated yield 0.060 g, 66%; brown liquid; $^1\text{H NMR}$ (500 MHz, CDCl_3): *major diastereomer*: δ 8.25 (s, 1H), 7.33–7.27 (m, 2H), 7.24–7.13 (m, 3H), 6.56 (d, $J = 15.5$ Hz, 1H), 5.93 (dt, $J = 15.5, 7.0$ Hz, 1H), 3.50 (d, $J = 7.0$ Hz, 2H), 2.65 (br-t, $J = 7.5$ Hz, 2H), 2.59 (br-t, $J = 7.5$ Hz, 2H), 1.89 (pent, $J = 7.5$ Hz, 2H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) *major diastereomer*: δ 146.2, 145.8, 139.9, 133.7, 131.4, 128.8, 128.7, 126.5, 124.2, 39.8, 34.0, 32.6, 21.7; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}} = 3526, 3026, 2845, 1602, 1495, 1452, 994, 957, 931, 748, 698$ cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{15}\text{H}_{17}\text{NO}$: 227.1310; found: 227.1306.

2-(2-Cyclopentyl-vinyl)-cyclopent-1-enecarbaldehyde oxime (8h):

Prepared according to the general procedure discussed above with 2-(2-cyclopentyl-vinyl)-cyclopent-1-enecarbaldehyde (0.34 mmol) and hydroxylamine hydrochloride, $R_F = 0.66$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; isolated yield 0.040 g, 57%; peach solid; mp = 123.4–128.0 °C; $^1\text{H NMR}$ (500 MHz, CDCl_3) *major oxime diastereomer*: δ 8.26 (s, 1H), 6.49 (d, $J = 15.5$ Hz, 1H), 5.79 (dd, $J = 15.5, 8.0$ Hz, 1H), 2.67–2.57 (m, 4H), 2.56–2.49 (m, 1H), 1.90 (pent, $J = 7.5$ Hz, 2H), 1.86–1.78 (m, 2H),

1.71–1.63 (m, 2H), 1.62–1.55 (m, 2H), 1.37–1.28 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) *major oxime diastereomer*: δ 146.8, 146.5, 140.6, 130.2, 121.3, 44.2, 34.0, 33.4, 32.6, 24.4, 21.8; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}}$ = 3261, 2951, 2868, 1637, 1617, 996, 956, 935 cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{13}\text{H}_{19}\text{NO}$: 205.1467; found: 205.1459.

2-(2-Cyclohexyl-vinyl)-cyclopent-1-enecarbaldehyde oxime (8i):

Prepared according to the general procedure discussed above with **6h** (0.49 mmol, 1.00 equiv) and hydroxylamine hydrochloride, R_F = 0.56, 20% EtOAc:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase; isolated yield 0.060 g, 56%; cream colored solid; mp = 136.2–137.9 °C; ^1H NMR (500 MHz, CDCl_3) *major diastereomer*: δ 8.27 (s, 1H), 6.47 (d, J = 15.5 Hz, 1H), 5.74 (dd, J = 15.5, 7.5 Hz, 1H), 2.63 (t, J = 7.5 Hz, 2H), 2.59 (t, J = 7.5 Hz, 2H), 1.90 (pent, J = 7.5 Hz, 2H), 1.78–1.71 (m, 4H), 1.70–1.63 (m, 1H), 1.35–1.23 (m, 3H), 1.22–1.06 (m, 3H); ^{13}C NMR (125 MHz, CDCl_3) *major diastereomer*: δ 146.7, 146.1, 141.1, 130.6, 120.6, 41.5, 33.9, 33.0, 32.6, 26.2, 26.1, 21.8; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}}$ = 3267, 2994, 2921, 2848, 1637, 1585, 1451, 1003, 955, 933 cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{14}\text{H}_{21}\text{NO}$: 219.1623; found: 219.1627.

2-[2-(3-Methoxy-phenyl)-vinyl]-cyclopent-1-enecarbaldehyde oxime (8j):

Prepared according to the general procedure discussed above with **6i** (0.35 mmol, 1.00 equiv) and hydroxylamine hydrochloride, R_F = 0.41, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; isolated yield 0.040 g, 51%; off-white solid; mp = 156.4–158.8 °C; ^1H NMR (500 MHz, CDCl_3): δ 8.41 (s, 1H), 7.28–7.24 (m, 1H), 7.22 (d, J = 16.0 Hz, 1H), 7.07–7.03 (m, 1H), 6.99–6.97 (m, 1H), 6.82 (ddd, J = 8.2, 2.4, 0.8 Hz), 6.58 (d, J = 16.0 Hz, 1H), 3.85 (s, 3H), 2.78–2.68 (m, 4H), 1.98 (pent, J = 7.5 Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 160.1, 146.6, 145.4, 138.7, 133.8, 132.0, 129.9, 121.5, 119.6, 114.0, 111.8, 55.4, 33.8, 32.9, 21.8; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}}$ = 3164, 3002, 2837, 1603, 1575, 1490, 1433, 1261, 1044, 950, 770, 684 cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{15}\text{H}_{17}\text{NO}_2$: 234.1259; found: 243.1258.

2-[2-(3,5-Difluoro-phenyl)-vinyl]-cyclopent-1-enecarbaldehyde oxime (8k):

Prepared according to the general procedure discussed above with **6j** (0.30 mmol, 1.00 equiv) and hydroxylamine hydrochloride, R_F = 0.55, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; isolated yield 0.066 g, 88%; pale-pink solid; mp = 171.4–176.1 °C; ^1H NMR (500 MHz, CDCl_3): δ 8.38 (s, 1H), 7.43 (br-s, 1H), 7.20 (d, J = 16.0 Hz, 1H), 6.97–6.92 (m, 2H), 6.72–6.67 (m, 1H), 6.50 (d, J = 16.0 Hz, 1H), 2.77–2.69 (m, 4H), 1.99 (pent, J = 7.5 Hz, 2H); ^{13}C NMR (125 MHz, $(\text{CD}_3)_2\text{CO}$): δ 164.1 (dd, J = 250.0, 13.0 Hz), 145.8, 143.1, 142.6, 138.0, 129.6 (t, J = 3.0 Hz), 125.4, 110.2 (dd, J = 19.5, 5.5 Hz), 103.1 (t, J = 26.5 Hz), 33.9, 33.7, 23.3; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}}$ = 3181, 3078, 2921, 2851, 1612, 1590, 1437, 1122, 980, 951 cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{14}\text{H}_{13}\text{F}_2\text{NO}$: 249.0965; found: 249.0970.

2-Phenyl-cyclopent-1-enecarbaldehyde oxime (8l):

Prepared according to the general procedure discussed above with **6k** (0.86 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.34$, 10% MTBE: hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; isolated yield 0.118 g, 74%; yellow solid; mp = 105.1–107.1 °C; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.10 (s, 1H), 7.39–7.35 (m, 2H), 7.32–7.27 (m, 3H), 2.90–2.84 (m, 2H), 2.79–2.74 (m, 2H), 2.02 (pent, $J = 7.5$ Hz, 2H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 148.6, 148.2, 136.7, 131.8, 128.4, 128.0, 127.8, 38.4, 33.0, 22.0; IR (ATR- CDCl_3): $\bar{\nu}_{max} = 3261, 3055, 3953, 3849, 1601, 1620, 1493, 967, 760, 698\text{ cm}^{-1}$; HRMS (EI): m/z calculated for $\text{C}_{12}\text{H}_{13}\text{NO}$: 187.0997; found: 187.1000.

2-*p*-Tolyl-cyclopent-1-enecarbaldehyde oxime (8m):

Prepared according to the general procedure discussed above with **6l** (0.46 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.39$, 20% MTBE: hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 2.5% isocratic hold; isolated yield 0.065 g, 70%; yellow solid; mp = 157.0–159.5 °C; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.20 (s, 1H), 7.34 (s, 4H), 2.96–2.91 (m, 2H), 2.87–2.82 (m, 2H), 2.45 (s, 3H), 2.09 (pent, $J = 7.5$ Hz, 2H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 149.2, 148.5, 137.9, 133.8, 130.7, 129.2, 128.1, 38.5, 33.1, 22.1, 21.4; IR (ATR- CDCl_3): $\bar{\nu}_{max} = 3529, 2961, 2853, 1620, 1513, 1447, 969, 822\text{ cm}^{-1}$; HRMS (EI): m/z calculated for $\text{C}_{13}\text{H}_{15}\text{NO}$: 201.1154; found: 201.1153.

2-(4-*tert*-Butyl-phenyl)-cyclopent-1-enecarbaldehyde oxime (8n):

Prepared according to the general procedure discussed above with **6m** (0.58 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.50$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; isolated yield 0.060 g, 47%; white solid; mp = 136.0–137.5 °C; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.14 (s, 1H), 7.41–7.37 (m, 2H), 7.25–7.20 (m, 2H), 2.90–2.84 (m, 2H), 2.80–2.73 (m, 2H), 2.01 (pent, $J = 7.5$ Hz, 2H), 1.35 (s, 9H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 151.1, 148.8, 148.2, 133.8, 130.9, 127.9, 125.4, 39.4, 34.8, 33.1, 31.4, 22.1; IR (ATR- CDCl_3): $\bar{\nu}_{max} = 3270, 3036, 2960, 2868, 1617, 1508, 1462, 1442, 969, 834\text{ cm}^{-1}$; HRMS (EI): m/z calculated for $\text{C}_{16}\text{H}_{21}\text{NO}$: 243.1623; found: 243.1620.

2-(4-Methoxy-phenyl)-cyclopent-1-enecarbaldehyde oxime (8o):

Prepared according to the general procedure discussed above with **6n** (0.76 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.32$, 20% MTBE:hexanes; purified using automated flash column chromatography using an EtOAc: hexanes gradient mobile phase employing a 2.5% isocratic hold; isolated yield 0.085 g, 51%; yellow solid; mp = 103.0–106.0 °C; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.12 (s, 1H), 7.24–7.21 (m, 2H), 6.92–6.88 (m, 2H), 3.83 (s, 3H), 2.86–2.82 (m, 2H), 2.78–2.73 (m, 2H), 2.00 (pent, $J = 7.5$ Hz, 2H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 159.5, 148.5, 148.1, 130.1, 129.4, 129.2, 114.0, 55.4, 38.4, 30.1, 22.0; IR (ATR- CDCl_3): $\bar{\nu}_{max} = 3270, 3044, 2838, 1607, 1510, 1462, 1441, 1249, 1178,$

1033, 965, 832 cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{13}\text{H}_{15}\text{NO}_2$: 217.1103; found: 217.1098.

2-(4-Dimethylamino-phenyl)-cyclopent-1-enecarbaldehyde oxime (8p):

Prepared according to the general procedure discussed above with **6o** (0.35 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.43$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 2.5% isocratic hold; isolated yield 0.049 g, 60%; beige solid; mp = 186.0–187.5 °C; ^1H NMR (500 MHz, CDCl_3): δ 8.20 (s, 1H), 7.22–7.18 (m, 2H), 6.72 (br-d, $J = 8.5$ Hz, 2H), 2.98 (s, 6H), 2.86–2.81 (m, 2H), 2.77–2.72 (m, 2H), 1.98 (pent, $J = 7.5$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 150.2, 148.8, 148.6, 129.22, 129.2X (overlaps with 129.22), 112.22, 40.6, 38.2, 33.1, 22.0; IR (ATR- CDCl_3): $\bar{\nu}_{max} = 3195, 2953, 2853, 1610, 1521, 1359, 965, 905, 727$ cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{14}\text{H}_{18}\text{N}_2\text{O}$: 230.1419; found: 230.1425.

4-[2-(Hydroxyimino-methyl)-cyclopent-1-enyl]-*N*-(2-methoxy-ethyl)-benzamide (8q):

Prepared according to the general procedure discussed above with 4-(2-formyl-cyclopent-1-enyl)-*N*-(2-methoxy-ethyl)-benzamide (0.37 mmol) and hydroxylamine hydrochloride, $R_F = 0.32$, 75% EtOAc:hexanes; purified using automated flash column chromatography using an EtOAc:hexanes gradient mobile phase; isolated yield 0.050 g, 48%; white film; ^1H NMR (500 MHz, CDCl_3): δ 8.33 (br-s, 1H), 8.07 (s, 1H), 7.80–7.70 (m, 2H), 7.35–7.30 (m, 2H), 6.65 (br-t, $J = 5.0$ Hz, 1H), 3.70–3.65 (m, 2H), 3.60–3.56 (m, 2H), 3.41 (s, 3H), 2.89–2.84 (m, 2H), 2.79–2.74 (m, 2H), 2.02 (pent, $J = 7.5$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 167.2, 147.5, 147.1, 140.0, 133.7, 133.0, 128.3, 127.2, 71.4, 59.0, 38.8, 38.4, 32.3, 22.1; IR (ATR- CDCl_3): $\bar{\nu}_{max} = 3289, 3047, 2926, 2852, 1638, 1609, 1542, 1304, 1117, 966, 853, 732$ cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{16}\text{H}_{20}\text{N}_2\text{O}_3$: 288.1474; found: 288.1479.

2-(4-Methylsulfonyl-phenyl)-cyclopent-1-enecarbaldehyde oxime (8r):

Prepared according to the general procedure discussed above with **6p** (0.73 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.34$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 10% isocratic hold; isolated yield 0.097 g, 57%; yellow solid; mp = 141.0–142.5 °C; ^1H NMR (500 MHz, CDCl_3): δ 8.10 (s, 1H), 7.26–7.22 (m, 2H), 7.21–7.17 (m, 2H), 2.87–2.81 (m, 2H), 2.78–2.73 (m, 2H), 2.49 (s, 3H), 2.01 (pent, $J = 7.5$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 148.3, 148.2, 138.6, 133.4, 131.2, 128.6, 126.4, 38.3, 33.1, 22.1, 15.8; IR (ATR- CDCl_3): $\bar{\nu}_{max} = 3256, 3002, 2951, 2924, 2850, 1623, 1605, 1591, 965, 818$ cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{13}\text{H}_{15}\text{NOS}$: 233.0874; found: 233.0875.

2-Benzo [1,3] dioxol-5-yl-cyclopent-1-enecarbaldehyde oxime (8s):

Prepared according to the general procedure discussed above with **6q** (0.41 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.34$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; isolated yield 0.062 g, 65%; tan solid; mp = 139.0–141.5 °C; ^1H NMR (500 MHz, CDCl_3): δ 8.10 (s, 1H), 6.82–6.79 (m, 1H), 6.77–6.74 (m, 2H), 5.98 (s,

2H), 2.84–2.79 (m, 2H), 2.77–2.71 (m, 2H), 2.00 (pent, $J = 7.5$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 148.5, 148.1, 147.8, 147.5, 130.7, 122.03, 122.0X (overlaps with 122.03), 108.5, 108.4, 101.3, 38.6, 33.1, 22.0; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}} = 3271, 2957, 2895, 2850, 1621, 1605, 1504, 1487, 1440, 1248, 1039, 936 \text{ cm}^{-1}$; HRMS (EI): m/z calculated for $\text{C}_{13}\text{H}_{13}\text{NO}_3$: 231.0895; found: 231.0889.

2-(3,3-Dimethyl-butyl)-cyclopent-1-enecarbaldehyde oxime (8t):

Prepared according to the general procedure discussed above with 2-(3,3-dimethyl-butyl)-cyclopent-1-enecarbaldehyde (0.33 mmol) and hydroxylamine hydrochloride, $R_F = 0.55$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 7.5% isocratic hold; isolated yield 0.032 g, 50%; amorphous; ^1H NMR (500 MHz, CDCl_3): δ 8.10 (s, 1H), 2.54 (br-t, $J = 7.5$ Hz, 2H), 2.45 (br-t, $J = 7.5$ Hz, 2H), 2.24–2.18 (m, 2H), 1.86 (pentet, $J = 7.5$ Hz, 2H), 1.31–1.24 (m, 2H), 0.92 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3): δ 152.2, 146.5, 128.6, 42.7, 37.2, 30.6, 29.3, 24.1, 21.9; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}} = 3290, 2953, 2866, 1639, 1601, 904, 727, 650 \text{ cm}^{-1}$; HRMS (EI): m/z calculated for $\text{C}_{12}\text{H}_{21}\text{NO}$: 195.1623; found: 195.1620.

2-Vinyl-cyclopent-1-enecarbaldehyde oxime (8u):

Prepared according to the general procedure discussed above with 2-vinyl-cyclopent-1-enecarbaldehyde (0.50 mmol) and hydroxylamine hydrochloride, $R_F = 0.54$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 7.5% isocratic hold; isolated yield 0.014 g, 20%; brown oil; ^1H NMR (500 MHz, CDCl_3) *major oxime diastereomer*: δ 8.28 (s, 1H), 6.81 (dd, $J = 17.0, 10.0$ Hz, 1H), 5.29 (d, $J = 17.5$ Hz, 1H), 5.27 (d, $J = 10.0$ Hz, 1H), 2.67 (t, $J = 7.5$ Hz, 2H), 2.62 (t, $J = 7.5$ Hz, 2H), 1.92 (pent, $J = 7.5$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3) *major oxime diastereomer*: δ 146.4, 145.6, 133.2, 129.5, 117.5, 33.2, 32.8, 21.6; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}} = 3271, 3093, 2925, 2849, 1603, 1009, 992, 937, 909, 733 \text{ cm}^{-1}$; HRMS (EI): m/z calculated for $\text{C}_8\text{H}_{11}\text{NO}$ (M – H): 136.0757; found: 136.0765.

3-Phenyl-6,7-dihydro-5H-[2] pyridine (8v):

Material afforded as a byproduct to chromatographic purification of **8f** above. $R_F = 0.80$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 5% isocratic hold; film; ^1H NMR (500 MHz, CD_3OD): δ 8.42 (s, 1H), 7.88–7.84 (m, 2H), 7.71 (s, 1H), 7.49–7.44 (m, 2H), 7.42–7.40 (m, 1H), 3.5–2.98 (m, 4H), 2.17 (pent, $J = 7.5$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ 157.5, 157.0, 145.5, 140.8, 140.7, 129.8, 129.7, 128.2, 118.9, 33.7, 30.8, 26.2; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}} = 3201, 3029, 2847, 1606, 1556, 1475, 1448, 1073, 736, 694 \text{ cm}^{-1}$; HRMS (EI): m/z calculated for $\text{C}_{14}\text{H}_{13}\text{N}$: 195.1048; found: 195.1048.

2-Styryl-cyclohex-1-enecarbaldehyde oxime (9a):

Prepared according to the general procedure discussed above with **7a** (0.54 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.50$, 20% MTBE: hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 2.5% isocratic hold; isolated yield 0.061 g, 50%; white solid; mp = 142.0–

143.0 °C; ¹H NMR (500 MHz, CDCl₃): δ 8.61 (s, 1H), 7.47–7.43 (m, 2H), 7.39–7.32 (m, 3H), 7.28–7.23 (m, 1H), 6.70 (d, *J* = 15.9 Hz, 1H), 2.49–2.41 (m, 4H), 1.78–1.65 (m, 4H); ¹³C NMR (125 MHz, CDCl₃): δ 149.1, 139.1, 167.5, 129.6, 129.3, 128.8, 127.9, 126.7, 125.0, 26.9, 25.5, 22.4, 22.1; IR (ATR-CDCl₃): $\bar{\nu}_{max}$ = 3289, 3056, 2931, 2861, 1599, 1582, 1495, 950, 748, 691 cm⁻¹; HRMS (EI): *m/z* calculated for C₁₅H₁₇NO: 227.1310; found: 227.1304.

2-(2-*p*-Tolyl-vinyl)-cyclohex-1-enecarbaldehyde oxime (9b):

Prepared according to the general procedure discussed above with **7b** (0.35 mmol, 1.00 equiv) and hydroxylamine hydrochloride, R_F = 0.49, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 7.5% isocratic hold; isolated yield 0.059 g, 69%; white solid; mp = 145.5–155.5 °C; ¹H NMR (500 MHz, CDCl₃): δ 8.60 (s, 1H), 7.34 (d, *J* = 8.0 Hz, 2H), 7.32 (d, *J* = 16.0 Hz, 1H), 7.15 (d, *J* = 8.0 Hz, 2H), 6.67 (d, *J* = 16.0 Hz, 1H), 2.49–2.40 (br-m, 4H), 2.35 (s, 3H), 1.77–1.65 (m, 4H); ¹³C NMR (125 MHz, CDCl₃): δ 149.3, 139.3, 138.0, 134.7, 129.6, 129.6, 128.8, 126.7, 124.0, 26.9, 25.5, 22.4, 22.1, 21.4; IR (ATR-CDCl₃): $\bar{\nu}_{max}$ = 3249, 3053, 3017, 2931, 2861, 1611, 1578, 1444, 950, 800 cm⁻¹; HRMS (EI): *m/z* calculated for C₁₆H₁₉NO: 241.1467; found: 241.1465.

2-(2-*p*-Tolyl-vinyl)-benzaldehyde oxime (13a):

Prepared according to the general procedure discussed above with **11a** (0.52 mmol, 1.00 equiv) and hydroxylamine hydrochloride, R_F = 0.36, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 10% isocratic hold; isolated yield 0.050 g, 41%; pale-yellow solid; mp = 125.7–127.3 °C; ¹H NMR (500 MHz, CDCl₃): δ 8.55 (s, 1H), 7.70 (dd, *J* = 7.7, 1.3 Hz, 1H), 7.67 (d, *J* = 8.0 Hz, 1H), 7.57 (br-s, 1H), 7.49–7.37 (m, 4H), 7.34–7.26 (m, 1H), 7.18 (d, *J* = 7.7 Hz, 2H), 6.96 (d, *J* = 16.0 Hz, 1H), 2.38 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 149.5, 138.2, 137.3, 134.5, 132.5, 130.1, 129.6, 129.5, 127.6, 126.9, 126.8, 124.6, 21.4; IR (ATR-CDCl₃): $\bar{\nu}_{max}$ = 3307, 3056, 3027, 2920, 1634, 1597, 1515, 1485, 1451, 1302, 961, 804, 753 cm⁻¹; HRMS (EI): *m/z* calculated for C₁₆H₁₅NO: (M – H) 236.1070; found: 236.1068.

2-[2-(4-Methoxy-phenyl)-vinyl]-benzaldehyde oxime (13b):

Prepared according to the general procedure discussed above with **11b** (0.81 mmol, 1.00 equiv) and hydroxylamine hydrochloride, R_F = 0.36, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase; isolated yield 0.090 g, 65%; pale-yellow solid; mp = 142.3–144.2 °C; ¹H NMR (500 MHz, CDCl₃): δ 8.52 (s, 1H), 7.67 (dd, (*J* = 7.8, 1.3 Hz, 1H), 7.59 (d, *J* = 7.8 Hz, 1H), 7.47–7.43 (m, 2H), 7.39–7.35 (m, 1H), 7.34 (d, *J* = 16.3 Hz, 1H), 7.28–7.26 (m, 1H), 6.95–6.88 (m, 3H), 3.83 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 159.7, 149.6, 137.4, 132.0, 130.0, 129.97, 129.3, 128.1, 127.5, 127.4, 126.7, 123.4, 114.2, 55.4; IR (ATR-CDCl₃): $\bar{\nu}_{max}$ = 3193, 2990, 2966, 2912, 2838, 1603, 1511, 1246, 1176, 1030, 980, 959, 824, 811, 761, 546, 517 cm⁻¹; HRMS (EI): *m/z* calculated for C₁₆H₁₅NO₂: 253.1103; found: 253.1091.

4'-Methoxy-biphenyl-2-carbaldehyde oxime (13c):

Prepared according to the general procedure discussed above with **11c** (0.65 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.39$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 20% isocratic hold; isolated yield 0.074 g, 51%; amorphous; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.12 (s, 1H), 7.89 (7.3, 1.8 Hz, 1H), 7.42 (dt, $J = 7.5, 1.3$ Hz, 1H), 7.38–7.31 (m, 2H), 7.26–7.21 (m, 3H), 7.00–6.96 (m, 2H), 3.87 (s, 3H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 159.3, 150.2, 142.1, 132.0, 131.0, 130.5, 129.8, 129.75, 128.3, 127.4, 114.0, 55.1; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}} = 3299, 3068, 2835, 1610, 1515, 1482, 1442, 1298, 1245, 1178, 955, 834, 763$ cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{14}\text{H}_{13}\text{NO}_2$: 227.0946; found: 227.0947.

2-Styryl-pyridine-3-carbaldehyde oxime (14a):

Prepared according to the general procedure discussed above with **12a** (0.32 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.23$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 30% isocratic hold; isolated yield 0.030 g, 42%; white solid; mp = 168.1–171.1 °C; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.62 (dd, $J = 4.7, 1.8$ Hz, 1H), 8.54 (s, 1H), 7.98 (dd, $J = 8.0, 1.8$ Hz, 1H), 7.81 (d, $J = 15.6$ Hz, 1H), 7.61–7.57 (m, 2H), 7.56 (br-s, 1H), 7.49 (d, $J = 15.6$ Hz, 1H), 7.40–7.35 (m, 2H), 7.33–7.28 (m, 1H), 7.18 (dd, $J = 8.0, 4.7$ Hz, 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 153.2, 150.6, 147.7, 136.8, 135.9, 135.4, 128.9, 128.8, 127.6, 125.3, 123.3, 122.3; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}} = 3058, 2879, 2772, 1634, 1578, 1494, 904, 727, 650$ cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{14}\text{H}_{12}\text{N}_2\text{O}$: (M – H) 223.0866; found: 223.0872.

2-(2-*p*-Tolyl-vinyl)-pyridine-3-carbaldehyde oxime (14b):

Prepared according to the general procedure discussed above with **12b** (0.60 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.16$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 35% isocratic hold; isolated yield 0.101 g, 72%; white solid; mp = 143.9–146.5 °C; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.62 (dd, $J = 4.7, 1.8$ Hz, 1H), 8.56 (br-s, 1H), 7.99 (dd, $J = 7.9, 1.8$ Hz, 1H), 7.80 (d, $J = 15.9$ Hz, 1H), 7.53–7.48 (m, 3H), 7.45 (d, $J = 15.9$ Hz, 1H), 7.22–7.16 (m, 3H), 2.38 (s, 3H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 153.1, 149.9, 147.3, 139.2, 136.7, 135.9, 133.8, 129.7, 127.6, 125.5, 122.1, 121.5, 21.5; IR (ATR- CDCl_3): $\bar{\nu}_{\text{max}} = 2986, 2883, 1636, 1581, 1510, 1477, 1407, 1066, 1058, 980, 812, 798$ cm^{-1} ; HRMS (EI): m/z calculated for $\text{C}_{15}\text{H}_{14}\text{N}_2\text{O}$: (M – H) 237.1022; found: 237.1029.

2-[2-(4-Methoxy-phenyl)-vinyl]-pyridine-3-carbaldehyde oxime (14c):

Prepared according to the general procedure discussed above with **12c** (0.21 mmol, 1.00 equiv) and hydroxylamine hydrochloride, $R_F = 0.11$, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 15% isocratic hold; isolated yield 0.026 g, 47%; amorphous; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 8.59 (dd, $J = 4.7, 1.7$ Hz, 1H), 8.54 (s, 1H), 7.96 (dd, $J = 7.9, 1.7$ Hz, 1H), 7.77 (d, $J = 15.7$ Hz, 1H), 7.56–7.52 (m, 2H), 7.44 (br-s, 1H), 7.35 (d, $J = 15.7$ Hz, 1H), 7.15 (dd, $J = 7.9, 4.7$ Hz, 1H), 6.93–6.88 (m, 2H), 3.84 (s, 3H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ

160.3, 153.6, 150.5, 147.6, 135.6, 135.3, 129.5, 129.0, 125.0, 121.9, 121.0, 114.3, 55.5; IR (ATR-CDCl₃): $\bar{\nu}_{max}$ = 3162, 3064, 2837, 2771, 1632, 1605, 1575, 1511, 1427, 1253, 1174, 1031, 971, 826 cm⁻¹; HRMS (EI): m/z calculated for C₁₅H₁₄N₂O₂: 254.1055; found: 254.1052.

2-Phenyl-pyridine-3-carbaldehyde oxime (14d):

Prepared according to the general procedure discussed above with **12d** (0.44 mmol, 1.00 equiv) and hydroxylamine hydrochloride, R_F = 0.11, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 25% isocratic hold; isolated yield 0.061 g, 70%; white solid; mp = 103.2–104.7 °C; ¹H NMR (500 MHz, CDCl₃): δ 8.71 (dd, J = 4.8, 1.8 Hz, 1H), 8.22 (dd, J = 8.0, 1.8 Hz, 1H), 8.16 (br-s, 1H), 7.55–7.51 (m, 2H), 7.50–7.42 (m, 3H), 7.32 (dd, J = 8.0, 4.8 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 158.5, 150.5, 148.5, 138.6, 134.6, 129.8, 129.0, 128.6, 126.1, 122.5; IR (ATR-CDCl₃): $\bar{\nu}_{max}$ = 3060, 2865, 1564, 1439, 1420, 976, 880, 747, 701 cm⁻¹; HRMS (EI): m/z calculated for C₁₂H₁₀N₂O: 198.0793; found: 198.0793.

2-*p*-Tolyl-pyridine-3-carbaldehyde oxime (14e):

Prepared according to the general procedure discussed above with **12e** (0.22 mmol, 1.00 equiv) and hydroxylamine hydrochloride, R_F = 0.21, 20% MTBE: hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 15% isocratic hold; isolated yield 0.030 g, 63%; white solid; mp = 203.6–206.2 °C; ¹H NMR (500 MHz, CDCl₃): δ 8.70 (dd, J = 4.7, 1.7 Hz, 1H), 8.19 (dd, J = 8.0, 1.7 Hz, 1H), 8.17 (s, 1H), 7.45–7.41 (m, 2H), 7.35 (br-s, 1H), 7.30–7.27 (m, 3H), 2.43 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 158.6, 150.6, 148.9, 138.9, 135.8, 134.6, 129.8, 129.3, 125.8, 122.2, 21.5; IR (ATR-CDCl₃): $\bar{\nu}_{max}$ = 3163, 3052, 2990, 2871, 2764, 1615, 1582, 1512, 1424, 977, 881, 827, 773 cm⁻¹; HRMS (EI): m/z calculated for C₁₃H₁₂N₂O: 212.0950; found: 212.0951.

2-(4-Methoxy-phenyl)-pyridine-3-carbaldehyde oxime (14f):

Prepared according to the general procedure discussed above with **12f** (0.32 mmol, 1.00 equiv) and hydroxylamine hydrochloride, R_F = 0.08, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 10% isocratic hold; isolated yield 0.061 g, 84%; pale-yellow solid; mp = 208.4–212.1 °C; ¹H NMR (500 MHz, CDCl₃): δ 8.71–8.68 (m, 1H), 8.21–8.16 (br-m, 2H), 7.52–7.47 (m, 2H), 7.30–7.26 (m, 1H), 7.05–6.98 (m, 2H), 3.88 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 160.4, 158.2, 150.6, 149.0, 134.7, 131.3, 131.1, 125.7, 122.0, 114.1, 55.5; IR (ATR-CDCl₃): $\bar{\nu}_{max}$ = 3163, 3068, 2829, 2764, 1608, 1581, 1515, 1423, 1250, 1177, 903, 726 cm⁻¹; HRMS (EI): m/z calculated for C₁₃H₁₂N₂O₂: 228.0899; found: 228.0907.

3-Styryl-thiophene-2-carbaldehyde oxime (16a):

Prepared according to the general procedure discussed above with **15a** (0.27 mmol, 1.00 equiv) and hydroxylamine hydrochloride, R_F = 0.51, 20% MTBE: hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 25% isocratic hold; isolated yield 0.038 g, 62%; light-brown solid; mp =

132.9–135.1 °C; ¹H NMR (500 MHz, CDCl₃): δ 8.56 (s, 1H), 7.51 (d, *J* = 8.0 Hz, 2H), 7.40–7.35 (m, 2H), 7.34–7.28 (m, 2H), 7.26–7.23 (m, 1H), 7.14 (s, 1H), 7.02 (d, *J* = 16.2 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 144.1, 140.5, 137.0, 131.5, 130.4, 128.9, 128.3, 127.4, 126.7, 125.7, 120.0; HRMS (EI): *m/z* calculated for C₁₃H₁₁NOS: 229.0561; found: 229.0555.

3-(4-Methoxy-phenyl)-thiophene-2-carbaldehyde oxime (16b):

Prepared according to the general procedure discussed above with **15b** (0.24 mmol, 1.00 equiv) and hydroxylamine hydrochloride, *R_F* = 0.20, 20% MTBE:hexanes; purified using automated flash column chromatography using an MTBE:hexanes gradient mobile phase employing a 15% isocratic hold; isolated yield 0.022 g, 38%; amorphous; ¹H NMR (500 MHz, CDCl₃): δ 7.70 (br-s, 1H), 7.55 (dd, *J* = 5.8, 0.7 Hz, 1H), 7.35–7.30 (m, 2H), 7.10 (d, *J* = 5.0 Hz, 1H), 6.99–6.95 (m, 2H), 3.85 (s, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 159.5, 146.1, 141.3, 131.0, 130.4, 128.53, 128.45, 124.9, 114.2, 55.5; IR (ATR-CDCl₃): $\bar{\nu}_{max}$ = 3215, 3100, 3002, 2932, 2841, 1608, 1575, 1528, 1249, 1178, 1031, 833 cm⁻¹; HRMS (EI): *m/z* calculated for C₁₂H₁₁NO₂S: 233.0510; found: 233.0511.

4.1. Minimum inhibitory concentration assays

4.1.1. Cell culture and in vitro functional assays—HEK293T cells were cultured in DMEM containing 10% FBS and 1% penicillin and streptomycin (P/S). To test the effects of the novel compounds on FGF-23-mediated activation of FGFR1/α-KL complex, HEK293T cells were transiently transfected with either empty expression vector or full-length human α-KL along with the ERK luciferase reporter system¹² and *Renilla* luciferase-null as internal control plasmid. Transfections were performed by electroporation using Cell Line Nucleofector Kit® according to the manufacturer's protocol (Amaxa, Inc., Gaithersburg, MD). Thirty-six hours after transfection, the transfected cells were treated with each of the newly synthesized compound (10⁻⁵ M) or selected compound with a range of 10⁻⁹ ~ 10⁻⁴ M in the presence or absence of 1 nM FGF23 for IC₅₀. After 5 h, the cells were lysed and luciferase activities measured using a Synergy® H4 Hybrid Multi-Mode Microplate Reader (Winooski, VT, USA) and Promega® Dual-Luciferase Reporter Assay System (Madison, WI, USA). The IC₅₀ values of the test compounds were obtained graphically from concentration-effect curves using Prism 5.0 (GraphPad Software Inc).

4.1.2. Cytotoxicity assays—HEK293T cells were cultured in DMEM containing 10% FBS and 1% penicillin and streptomycin (P/S). To test cytotoxicity of the selected compounds, HEK293T cells were seeded into 96-well plate at a density of 5 × 10⁴/well. The compound toxicity was evaluated by measuring lactate dehydrogenase (LDH) activity released in the media 5 h after the test compound or vehicle exposure using the CytoTox96 nonradioactive assay (Promega) and quantitated by measuring wavelength absorbance at 490 nm. The LDH released from the cells exposed to different concentrations (10⁻⁶ ~ 10⁻³ M) of the compound were normalized to the amount of LDH released from vehicle-treated cells receiving 10 μL of 10 × Lysis Solution (100%, maximum LDH release) and were corrected for baseline LDH released from vehicle-treated cells. The EC₅₀ values of the test compounds were obtained graphically from concentration-effect curves using Prism 5.0 (GraphPad Software Inc).

4.2. Statistical analysis

We evaluated differences between two groups by unpaired *t*-test. All values are expressed as means \pm S.D. All computations were performed using a commercial biostatistics software (GraphPad Software Inc. La Jolla, CA).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

The authors would also like to thank Zachary Z. Gulledge (TN Tech) for the preparation of **13a** and **14b** for cytotoxicity assays and Dr. Qiaoli Liang (UA) for acquisition of HRMS data

Funding sources

Financial support for this work was provided by the TN Tech Office of Research Economic Development and the Department of Chemistry (J.D.C.), as well as by a grant from the National Institutes of Health, R01-DK121132 (L.D.Q.). NSF MRI 1531870 is gratefully acknowledged for the acquisition of TN Tech's 500 MHz multinuclear NMR spectrometer with broad-band N₂ cryoprobe.

References

1. (a) Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. *J Clin Invest* 2003, 112, 642–646. [PubMed: 12952909] (b) Quarles LD. The bone and beyond: 'dem bones' are made for more than walking. *Nat Med* 2011, 17, 428–430. [PubMed: 21475236]
2. (a) Yuan B, Takaiwa M, Clemens TL, et al. aberrant pHEX function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. *J Clin Invest* 2008, 118, 722–734. [PubMed: 18172553] (b) Drezner MK. PHEX gene and hypophosphatemia. *Kidney Int* 2000, 57, 9–18. [PubMed: 10620182]
3. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. *Nat Genet.* 2006;38: 1310–1315. [PubMed: 17033621]
4. Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. *J Bone Miner Res.* 2003;18:1227–1234. [PubMed: 12854832]
5. (a) Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. *J Am Med Assoc.* 2011;305:2432–2439. (b) Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. *Circulation.* 2009;119:2545–2552. [PubMed: 19414634] (c) Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. *N Engl J Med.* 2008;359:584–592. [PubMed: 18687639]
6. Carpenter TO, Whyte MP, Imel EA, et al. Burosumab therapy in children with X-linked hypophosphatemia. *The New Engl J Med.* 2018;378:1987–1998. [PubMed: 29791829]
7. (a) Ryckaert JP, Cicotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. *J Comput Phys.* 1977;23:327–341. (b) Salomon-Ferrer R, Case DA, Walker RC. An overview of the amber biomolecular simulation package. *Wiley Interdisciplinary Review in Computational Molecular Science.* 2013;3:198–210. (c) Hornak V, Abel E, Okur A, Strockbine B, Roitberg A, Simmerling C. Comparison of multiple amber force fields and development of improved protein backbone parameters. *Proteins.* 2006;65:712–725. [PubMed: 16981200] (d) Cornell WD, Cieplak P, Bayly CI, et al. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. *J Am Chem Soc.* 1995;117:5179–5197.
8. (a) Velazquez HA, Riccardi D, Xiao Z, et al. Ensemble docking to difficult targets in early-state drug discovery: methodology and application to fibroblast growth factor 23. *Chem Biol Drug Des* 2018, 91, 491–504. [PubMed: 28944571] (b) Falcon WE, Ellingson SR, Smith JC, Baudry J. Ensemble

- docking in drug discovery: how many protein configurations from molecular dynamics simulations are needed to reproduce known ligand binding. *J Phys Chem B*, 2019, 123, 25, 5189–5195. [PubMed: 30695645] (c)Amaro RE, Baudry J, Chodura J, et al. Ensemble docking in drug discovery. *Biophys J* 2018, 114, 2271–2278. [PubMed: 29606412]
9. Xiao ZS, Riccardi D, Velazquez HA, et al. Title goes here. A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia. *Science Signaling* 2016, 9, ra113-Cover Story. [PubMed: 27879395]
 10. Aungst RA Jr, Chan C, Funk RL. Total synthesis of the sesquiterpene (+/-)-Illudin C via an intramolecular nitrile oxide cycloaddition. *Org Lett*. 2001;3:2611–2613. [PubMed: 11483073]
 11. For recent reviews see:(a)Molander GA, Canturk B. Organotrifluoroborates and monocoordinated palladium complexes as catalysts—a perfect combination for suzuki–miyaura coupling. *Angew Chem Int Ed*. 2009;48:9240–9261.(b)Molander GA, Ellis N. Organotrifluoroborates: protected boronic acids that expand the versatility of the suzuki coupling reaction. *Acc Chem Res*. 2007;40:275–286. [PubMed: 17256882]
 12. (a)Rawat vS, Sreedhar B. Iron-catalyzed borylation reactions of alkynes: an efficient synthesis of E-vinyl boronates. *Synlett*. 2014;25:1132–1136.(b)Zhao J, Niu Z, Fu H, Li Y. Ligand-free hydroboration of alkynes catalyzed by heterogeneous copper powder with high efficiency. *Chem Commun*. 2014;50:2058–2060.
 13. Arnold Z, Holý A. Synthetic reactions of dimethylformamide XIII. B-Bromoacraldehyde. *Collection of Czechoslovak Chem Commun*. 1961;26:3059–3073.
 14. (a)Bekele T, Brunette SR, Lipton MA. Synthesis and cycloaromatization of a cyclic enyne–allene prodrug. *J Org Chem*. 2003;68:8471–8479. [PubMed: 14575473] (b)Salem B, Delort E, Klotz P, Cyclocarbopalladation Suffert J. 5-Exo-dig cyclization versus direct stille cross-coupling reaction. The influence of the α , β -propargylic substitution. *Org Lett*. 2003;5:2307–2310. [PubMed: 12816435] (c)Salem B, Delort E, Klotz P, Cyclocarbopalladation Suffert J. 5-Exo-dig cyclization versus direct stille cross-coupling reaction. The influence of the α/β -propargylic substitution. *Org Lett*. 2003;5:2307–2310. [PubMed: 12816435] (d)Yoshida K, Takahasi H, Imamoto T. Synthesis of substituted benzenes and phenols by ring-closing metathesis. *Chem-A Eur J*. 2008;14:8246–8261.
 15. Attempts to adapt this sequence to the 7- or 8-membered ring derivatives were not successful.
 16. Boronic acids and pinacoldiborinates were effectively substituted for the potassium trifluoroborate in several examples. Please see supporting information for further details.
 17. For recent reviews see:(a)Molander GA, Canturk B. Organotrifluoroborates and monocoordinated palladium complexes as catalysts—a perfect combination for suzuki–miyaura coupling. *Angew Chem Int Ed*. 2009;48:9240–9261.(b)Molander GA, Ellis N. Organotrifluoroborates: protected boronic acids that expand the versatility of the suzuki coupling reaction. *Acc Chem Res*. 2007;40:275–286. [PubMed: 17256882]
 18. Chin A-L, Carrick JD. Modular approaches to diversified soft lewis basic complexants through suzuki-miyaura cross-coupling of bromoheteroarenes with organotrifluoroborates. *J Org Chem*. 2016;81:1106–1115. [PubMed: 26751755]
 19. Substitution of the requisite pinacol borinates for the preparation of several derivatives proceeded favorably under the conditions described. Please see supporting information.
 20. Aungst RA Jr, Chan C, Funk RL. Total synthesis of the sesquiterpene (+/-)-illudin C via and intramolecular nitrile oxide cycloaddition. *Org Lett*. 2001;3:2611–2613. [PubMed: 11483073]
 21. Additional synthetic and spectroscopic details are delineated in the supporting information of this paper.
 22. A scale-up batch afforded over 1.2 g of 1 with an overall yield of 50% over three steps from 5 in three days.
 23. Compound 6a in the supporting information.
 24. Additional efforts to reproduce this result synthetically were not achieved.Trost BM; Gutierrez AC Ruthenium catalyzed cycloisomerization-6 π -cyclization: a novel route to pyridines. *Org Lett* 2007, 9, 1473–1476. [PubMed: 17362020]
 25. (a)Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Adv Drug Deliv Rev. 2001;46:3–26. [PubMed: 11259830] (b)Lipinski CA. Lead and drug-like compounds. The rule of 5 revolution. Drug Discovery Today, Technologies. 2004;1:337–341. [PubMed: 24981612]

26. Please see supporting information for aldehyde structure numbers and relevant spectroscopic and chromatographic data.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Fig. 1. Original vHTS hit ZINC13407541 (1) and focus areas for analogue development.






Fig. 2. Comparison of analogues of 1 based on ERK reporter activities at the concentration of 10 μ M. Values (mean \pm SEM, $n = 3-5$) with different superscripts (a-e) are significantly different at $P < 0.05$.

**Scheme 1.**

Synthesis of compounds 2-10. Reagents and conditions: (i) PBr_3 , DMF, rt; (ii) $\text{Pd}(\text{OAc})_2$ (5 mol%), RuPhos (10 mol%), RBR_n (1.2 equiv), Cs_2CO_3 (3 equiv), Tol: H_2O (4:1), 110 °C, 16 h; (iii) $\text{NH}_2\text{OH}\cdot\text{HCl}$, NaOAc, EtOH / H_2O , rt.

**Scheme 2.**

Synthesis of compounds 11–14. Reagents and conditions: (i) Pd(OAc)₂ (5 mol%), RuPhos (10 mol%), RBR_n (1.2 equiv), CS₂CO₃ (3 equiv), Tol:H₂O (4:1), 110 °C, 16 h; (ii) NH₂OH·HCl, NaOAc, EtOH / H₂O, rt, 16 h.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

FGF-23 antagonists prepared based on the structure of the original hit.




Table 2Determination of efficacy (IC₅₀) and cytotoxicity (EC₅₀) for select potent analogues.

Compound	IC ₅₀ (μM)	EC ₅₀ (μM)
1	5.0	1.41 × 10 ³
13a	0.14	6.90 × 10 ²
8a	0.20	5.70 × 10 ²
8c	0.37	–
14b	0.39	2.41 × 10 ³
9b	0.52	–
8n	2.79	2.30 × 10 ²
8l	10.0	–
8o	12.3	1.91 × 10 ³

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript